Clinical and serological features of the « antiphospholipid syndrome » (APS) (abstract), Bibliographie Br J Rheumatol, vol.26, issue.1, p.19, 1987. ,
[Acquired hemorrhagic syndrome caused by a circulating anticoagulant; inhibition of the thromboplastic function of the blood platelets; description of a specific test], Le Sang, vol.25, issue.1, pp.1-15, 1954. ,
Thrombosis in systemic lupus erythematosus despite circulating anticoagulants, The Journal of Laboratory and Clinical Medicine, vol.62, pp.416-446, 1963. ,
Avortements à répétition, thromboses et anticoagulant circulant antithromboplastine. Trois observations, Nouv Presse Med, vol.9, pp.859-60, 1980. ,
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop, Arthritis & Rheumatism, vol.7, issue.7, pp.1309-1320, 1999. ,
DOI : 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), Journal of Thrombosis and Haemostasis, vol.75, issue.2, pp.295-306, 2006. ,
DOI : 10.1080/00313020310001643615
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor, The Lancet, vol.335, issue.8705, pp.1544-1591, 1990. ,
DOI : 10.1016/0140-6736(90)91374-J
Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease, The Lancet, vol.336, issue.8708, pp.117-118, 1990. ,
DOI : 10.1016/0140-6736(90)91697-9
Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: ?2-glycoprotein I (apolipoprotein H), 1990. ,
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin, Thromb Haemost, vol.66, pp.629-632, 1991. ,
Risk Factors for Venous and Arterial Thrombosis, Blood Transfusion = Trasfusione Del Sangue, vol.9, issue.2, pp.120-158, 2011. ,
??2-Glycoprotein I, the playmaker of the antiphospholipid syndrome, Clinical Immunology, vol.112, issue.2, pp.161-68, 2004. ,
DOI : 10.1016/j.clim.2004.02.012
The Pathogenesis of the Antiphospholipid Syndrome, New England Journal of Medicine, vol.368, issue.11, pp.1033-1077, 2013. ,
DOI : 10.1056/NEJMra1112830
Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I, Current Rheumatology Reports, vol.46, issue.1, pp.70-76, 2011. ,
DOI : 10.1007/s11926-010-0144-8
Anti-??2 glycoprotein I (??2GPI) autoantibodies recognize an epitope on the first domain of ??2GPI, Proceedings of the National Academy of Sciences, vol.70, issue.1, pp.15542-15588, 1998. ,
DOI : 10.1016/0076-6879(87)54085-X
??2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation, Atherosclerosis, vol.63, issue.2-3, pp.109-123, 1987. ,
DOI : 10.1016/0021-9150(87)90110-9
Beta 2-Glycoprotein I: A Plasma Inhibitor of the Contact Activation of the Intrinsic Blood Coagulation Pathway, Blood, vol.66, issue.17 5, pp.1086-91, 1985. ,
Synchronized Inhibition of the Phospholipid Mediated Autoactivation of Factor XII in Plasma by Beta 2-Glycoprotein I and Anti-Beta 2-Glycoprotein I, Thrombosis and Haemostasis, vol.73, issue.5, pp.798-804, 1995. ,
Prothrombinase activity of human platelets is inhibited by ??2-glycoprotein-I, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.884, issue.1, pp.142-191, 1986. ,
DOI : 10.1016/0304-4165(86)90237-0
Anticardiolipin Antibodies Block the Inhibition by Beta 2-Glycoprotein I of the Factor Xa Generating Activity of Platelets, Thrombosis and Haemostasis, vol.70, issue.2, pp.342-387, 1993. ,
Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro., Journal of Clinical Pathology, vol.46, issue.10, pp.908-919, 1993. ,
DOI : 10.1136/jcp.46.10.908
Pathogenesis of antiphospholipid syndrome: understanding the antibodies, Nature Reviews Rheumatology, vol.39, issue.6, pp.330-369, 2011. ,
DOI : 10.1038/nrrheum.2011.52
Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome, Blood Reviews, vol.22, issue.2, pp.93-105, 2008. ,
DOI : 10.1016/j.blre.2007.09.001
Antiphospholipid syndrome: pathogenic mechanisms, Autoimmunity Reviews, vol.2, issue.2, pp.86-93, 2003. ,
DOI : 10.1016/S1568-9972(02)00144-1
Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway, Immunobiology, vol.210, issue.10, pp.775-80, 2005. ,
DOI : 10.1016/j.imbio.2005.10.009
Antiphospholipid syndrome, The Lancet, vol.376, issue.9751, pp.1498-1509, 2010. ,
DOI : 10.1016/S0140-6736(10)60709-X
Lupus anticoagulants and the risk of a first episode of deep venous thrombosis, Journal of Thrombosis and Haemostasis, vol.97, issue.9, pp.1993-97, 2005. ,
DOI : 10.1111/j.1538-7836.2005.01485.x
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study, The Lancet Neurology, vol.8, issue.11, pp.998-1005, 2009. ,
DOI : 10.1016/S1474-4422(09)70239-X
The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment, Lupus, vol.5, issue.2_suppl, pp.55-62, 1998. ,
DOI : 10.1177/096120339800700214
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, vol.101, issue.5, pp.1827-1859, 2003. ,
DOI : 10.1182/blood-2002-02-0441
Mechanisms of Disease: antiphospholipid antibodies???from clinical association to pathologic mechanism, Nature Clinical Practice Rheumatology, vol.1, issue.4, pp.192-99, 2008. ,
DOI : 10.1038/ncprheum0740
A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants, Journal of Thrombosis and Haemostasis, vol.116, issue.4, pp.740-787, 2003. ,
DOI : 10.1016/S0049-3848(98)00144-3
??2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome, Blood, vol.104, issue.12, pp.3598-3602, 2004. ,
DOI : 10.1182/blood-2004-03-1107
Anti-??2-Glycoprotein I antibodies and thrombosis, Clinical Reviews in Allergy & Immunology, vol.93, issue.4, Suppl., pp.67-72, 1995. ,
DOI : 10.1007/BF02772250
IgG antibodies that recognize epitope Gly40-Arg43 in domain I of ??2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis, Blood, vol.105, issue.4, pp.1540-1585, 2005. ,
DOI : 10.1182/blood-2004-09-3387
How we diagnose the antiphospholipid syndrome, Blood, vol.113, issue.5, pp.985-94, 2009. ,
DOI : 10.1182/blood-2007-12-129627
Anti-??2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome, Blood, vol.102, issue.8, pp.2717-2740, 2003. ,
DOI : 10.1182/blood-2002-11-3334
Use of Single Point Mutations in Domain I of ??2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies, The Journal of Immunology, vol.169, issue.12, pp.7097-7103, 1950. ,
DOI : 10.4049/jimmunol.169.12.7097
Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human ??2-glycoprotein I: Mutation studies including residues R39 to R43, Arthritis & Rheumatism, vol.52, issue.1, pp.280-90, 2007. ,
DOI : 10.1002/art.22306
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study, Blood, vol.110, issue.4, pp.1178-83, 2007. ,
DOI : 10.1182/blood-2007-01-066043
Diagnosis of the antiphospholipid syndrome: A proposal for use of laboratory tests, Lupus, vol.96, issue.12, pp.144-148, 1998. ,
DOI : 10.1177/096120339800700232
Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies, Thrombosis and Haemostasis, vol.97, issue.6, pp.949-54, 2007. ,
DOI : 10.1160/TH06-10-0604
Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss*, Journal of Obstetrics and Gynaecology Research, vol.267, issue.2, pp.326-358, 2004. ,
DOI : 10.1046/j.1538-7836.2003.00022.x
14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends, 14th International Congress on Antiphospholipid Antibodies: Task Force Report on Antiphospholipid Syndrome Treatment Trends, pp.685-96, 2014. ,
DOI : 10.1016/j.autrev.2014.01.053
Rivaroxaban versus Warfarin to Treat Patients with Thrombotic Antiphospholipid Syndrome, with or without Systemic Lupus Erythematosus (RAPS): A Randomised, Controlled, Open-Label The Lancet, pp.426-436, 2016. ,
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?, Arthritis & Rheumatism, vol.8, issue.12, pp.1435-1471, 1987. ,
DOI : 10.1002/art.1780301219
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus, Arthritis & Rheumatism, vol.44, issue.3, pp.863-68, 2010. ,
DOI : 10.1002/art.27289
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort, Annals of the Rheumatic Diseases, vol.68, issue.2, pp.238-279, 2009. ,
DOI : 10.1136/ard.2008.093013
Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, but only in antiphospholipid positive patients ,
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies, Arthritis Care & Research, vol.52, issue.Suppl, pp.29-36, 2009. ,
DOI : 10.1002/art.24232
Antithrombotic Effects of Hydroxychloroquine in Primary Antiphospholipid Syndrome Patients, Journal of Thrombosis and Haemostasis: JTH, vol.52, issue.11 10, pp.1927-1956, 2013. ,
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial, Lupus, vol.11, issue.3, pp.301-307, 2016. ,
DOI : 10.1001/jama.291.5.576
A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome, Arthritis & Rheumatism, vol.12, issue.2, pp.464-71, 2013. ,
DOI : 10.1002/art.37759
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis & Rheumatism, vol.62, issue.Suppl, pp.3918-3948, 2011. ,
DOI : 10.1002/art.30613
Efficacy and Safety of Belimumab in Patients with Active Systemic Lupus Erythematosus: A Randomised ,
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus, Arthritis & Rheumatism, vol.111, issue.7, pp.2328-2365, 2012. ,
DOI : 10.1002/art.34400
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350827
Eculizumab and Renal Transplantation in a Patient with CAPS, New England Journal of Medicine, vol.362, issue.18, pp.1744-1789, 2010. ,
DOI : 10.1056/NEJMc0910965
Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab, Arthritis & Rheumatism, vol.362, issue.8, pp.2719-2742, 2012. ,
DOI : 10.1002/art.34440
Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation, American Journal of Transplantation, vol.64, issue.2, pp.459-65, 2014. ,
DOI : 10.1111/ajt.12540
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, Journal of Thrombosis and Haemostasis, vol.106, issue.2, pp.237-279, 2010. ,
DOI : 10.1111/j.1538-7836.2009.03674.x
Traitement du syndrome des anticorps antiphospholipides, La Revue de M??decine Interne, vol.33, issue.4, pp.217-239, 2012. ,
DOI : 10.1016/j.revmed.2012.01.007
Clinical Thrombotic Manifestations in SLE Patients With and Without Antiphospholipid Antibodies: A 5-year Follow-up, Clinical Reviews in Allergy & Immunology, vol.2, issue.1, pp.131-168, 2007. ,
DOI : 10.1007/s12016-007-0009-8
Antibody profiles for the diagnosis of antiphospholipid syndrome, Thrombosis and Haemostasis, vol.93, issue.6, pp.1147-52, 2005. ,
DOI : 10.1160/TH04-12-0839
Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile, Journal of Thrombosis and Haemostasis, vol.38, issue.8, pp.1527-1558, 2013. ,
DOI : 10.1111/jth.12264
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, vol.118, issue.17, pp.4714-4732, 2011. ,
DOI : 10.1182/blood-2011-03-340232
Idarucizumab for Dabigatran Reversal, New England Journal of Medicine, vol.373, issue.6, pp.511-531, 2015. ,
DOI : 10.1056/NEJMoa1502000
Management of Infection in Systemic Lupus Erythematosus Best Practice & Research, Clinical Rheumatology, vol.27, issue.3, pp.377-89, 2013. ,
Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events, Arthritis & Rheumatism, vol.34, issue.2, pp.504-516, 2012. ,
DOI : 10.1002/art.33340
GAPSS: the Global Anti-Phospholipid Syndrome Score, Rheumatology, vol.52, issue.8, pp.1397-1403, 2013. ,
DOI : 10.1093/rheumatology/kes388
URL : http://hdl.handle.net/2318/142476
The global anti-phospholipid syndrome score in primary APS, Rheumatology, vol.54, issue.1, pp.134-172, 2015. ,
DOI : 10.1093/rheumatology/keu307
Seronegative antiphospholipid syndrome, Annals of the Rheumatic Diseases, vol.62, issue.12, p.1127, 2003. ,
DOI : 10.1136/ard.2003.006163
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754381
Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers, Arthritis Research & Therapy, vol.16, issue.2, p.209, 2014. ,
DOI : 10.1182/blood-2011-01-333617
Diagnosis and classification of the antiphospholipid syndrome, Journal of Autoimmunity, vol.48, issue.49, pp.48-49, 2014. ,
DOI : 10.1016/j.jaut.2014.01.006
ABO(H) blood groups and vascular disease: a systematic review and meta-analysis, Journal of Thrombosis and Haemostasis, vol.359, issue.Suppl. 2, pp.62-71, 2007. ,
DOI : 10.1111/j.1538-7836.2007.02818.x
Accuracy of the First Fully Automated Method for Anti-cardiolipin and Anti-??2 Glycoprotein I Antibody Detection for the Diagnosis of Antiphospholipid Syndrome, Annals of the New York Academy of Sciences, vol.34, issue.1, pp.21-27, 2009. ,
DOI : 10.1111/j.1749-6632.2009.04659.x
Contribution of anti-??2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients, Rheumatology, vol.53, issue.7, pp.1215-1233, 2014. ,
DOI : 10.1093/rheumatology/keu003
IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis, Journal of Thrombosis and Haemostasis, vol.9, issue.Suppl. 1, pp.1530-1578, 2016. ,
DOI : 10.1007/s11926-007-0034-x
Double positivity of the IgG isotype of both anticardiolipin and anti-??2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data, Clinical Rheumatology, vol.12, issue.1, pp.2947-54, 2016. ,
DOI : 10.1016/j.humimm.2015.10.008
Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study, Annals of the Rheumatic Diseases, vol.70, issue.6, pp.1083-86, 2011. ,
DOI : 10.1136/ard.2010.142042
A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome, Rheumatology, vol.41, issue.8, pp.924-953, 2002. ,
DOI : 10.1093/rheumatology/41.8.924
Antiphospholipid Syndrome and Asymptomatic Carriers of Antiphospholipid Antibody: Prospective Analysis of 404 Individuals, The Journal of Rheumatology, vol.83, issue.31 8, pp.1560-67, 2004. ,
Update of the guidelines for lupus anticoagulant detection, Update of the Guidelines for Lupus Anticoagulant Detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, pp.1737-1777, 2009. ,
DOI : 10.1111/j.1538-7836.2009.03555.x
Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile, Lupus, vol.47, issue.3, 2017. ,
DOI : 10.1016/j.thromres.2015.04.031
[The clinical manifestations and thrombotic risk factors in primary antiphospholipid syndrome], Zhonghua Nei Ke Za Zhi, vol.55, issue.86 5, pp.386-91, 2016. ,
Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study, Annals of the Rheumatic Diseases, vol.68, issue.3, pp.397-99, 2009. ,
DOI : 10.1136/ard.2008.096669
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry, The American Journal of Medicine, vol.100, issue.5, pp.530-566, 1996. ,
DOI : 10.1016/S0002-9343(96)00060-5